[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06788977":3,"trial-entities:NCT06788977":139,"trial-summary:NCT06788977":142},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":25,"study_type":36,"primary_purpose":37,"phases":38,"enrollment_info":39,"interventions":42,"primary_outcomes":51,"secondary_outcomes":58,"sex":59,"minimum_age":60,"maximum_age":61,"healthy_volunteers":15,"eligibility_criteria":62,"std_ages":66,"locations":68,"central_contacts":86,"overall_officials":93,"references":97,"see_also_links":135},"NCT06788977","51001","External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy","CEFALY Pregnancy Registry","RECRUITING","2030-12","2026-04","2026-04-15","2024-11-25","Cefaly Technology","INDUSTRY",false,"This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry.\n\nThe main question it aims to answer is:\n\nIs external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy?\n\nThere are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.","This will be a prospective research registry from which retrospective research studies will derive. Individuals who are eligible to participate in the CEFALY Pregnancy Registry will be pregnant women who have migraines or headaches. Use of the external Trigeminal Neurostimulation (eTNS) device is not mandatory for participation in the registry, and the registry will include information from individuals who use and do not use eTNS (CEFALY) to treat their migraines or headaches before, during, and after pregnancy.\n\nThe ideal candidate for participation will be women within 14 weeks gestation at the time of screening enrollment, as this will minimize any recall bias. However, women in the second and third trimesters during screening and enrollment will not be excluded and may also participate in the registry. The registry will aim to enroll 550 participants per the inclusion and exclusion criteria.\n\nRegistry participation, including consent, screening, enrollment, and completion of registry surveys, will be completed online using a confidential survey platform accessed via a publicly available web-based link. Once the simple consent is acknowledged, the potential participant will enter their name, email, phone number and date of birth. The phone number, and email entered are required to conduct the registry data collection process.\n\nParticipants will then complete screening questions to assess their eligibility for the registry. If they meet all eligibility requirements, they will be required to upload sufficient evidence of a current intrauterine pregnancy. The registry investigators will verify the uploaded document for accuracy before enrollment. The participant's name and date of birth are required to validate a current pregnancy based on the required uploaded documents during the screening process.\n\nIf eligible and documentation of current pregnancy is confirmed, the investigators will enroll the participant in the registry and start the survey process. Enrolled participants who have agreed to participate in the registry will receive an invitation to the requested surveys via automated email and short message service (SMS) text. The links provided in the email and SMS text will automatically direct the participant to the appropriate survey based on the timing of their enrollment, estimated due date, pregnancy status, and date of completion of prior surveys. Before each survey attempt, enrolled participants will need to verify their identity with an automated authentication code provided to their registered email address and phone number they provided during initial screening to verify their data and protect their entered health information.\n\nIn general, the surveys will ask questions about the participant's health history, their previous pregnancies (if applicable), current pregnancy, migraine or headache symptoms and migraine treatments and therapies. In addition, participants will be asked to complete several validated scales assessing the degree of migraine disability and mental health impact. If the participant indicates that they are using eTNS CEFALY during the registry process, they will also receive surveys about their eTNS use. Any unclear survey responses are found during periodic reviews as part of data quality assurance. In that case, study staff may contact the participant via email and\u002For phone call to clarify an answer or answers on the survey.\n\nIn most circumstances, the registry participants will be asked to complete up to six surveys. Based on preliminary registry testing, the enrollment (consent and screening) and baseline period will take participants approximately 20 minutes to complete. The five sets of surveys (1st, 2nd, 3rd trimester, early postpartum, and late postpartum) will take approximately 10 - 15 minutes for each participant to complete. Therefore, we estimate that the total participation time for most participants will be between 60 and 90 minutes. In some situations, the timing and number of surveys and time points requested will differ for some participants based on their responses.\n\nA link to a survey will be sent to the participant's email and phone via text for each of the following time points as indicated by the patient's estimated due date at time of enrollment.\n\nPre-pregnancy and Baseline: This survey will be sent following registry enrollment First trimester: This survey will be sent at 14 weeks gestation Second trimester: This survey will be sent at 28 weeks gestation Third trimester: This survey will be sent at 37 weeks gestation. Early postpartum: This survey will be sent 6 weeks following childbirth Late postpartum: This survey will be sent 12 weeks following childbirth\n\nIf the participant enrolls in the registry beyond any of the gestation periods described above, they will also be asked to complete the baseline and earlier trimester surveys before their current trimester following registry enrollment. If the participant delivers before 37 weeks gestation, the third-trimester survey will be sent following notification of childbirth.",[19,20,21,22,23,24],"Pregnancy","Migraine","Headache","Postpartum","Depression","Anxiety",[19,20,21,26,27,28,22,29,30,31,32,33,34,35],"Neuromodulation","Trigeminal Nerve Stimulation","External Trigeminal Nerve Stimulation","drug-free","medications","complementary therapy","alternative therapy","wholistic therapy","natural","non-invasive device","OBSERVATIONAL",null,[],{"count":40,"type":41},550,"ESTIMATED",[43],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":49},"DEVICE","external Trigeminal Nerve Stimulation","External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.\n\nThe CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.",[48],"External Trigeminal Nerve Stimulation (eTNS) group",[50],"supraorbital transcutaneous stimulator (STS)",[52,55],{"measure":53,"timeFrame":54},"Rate of miscarriage per trimester","through study completion average 2 years",{"measure":56,"description":57,"timeFrame":54},"Postpartum Bonding according to the Maternal-to-Infant Bonding Scale","The \"Maternal-to-Infant Bonding Scale\" is a scale which measures the mother's feelings regarding her child within the first few weeks after birth. The score of teh scale can range from 0 which denotes favorable or good outcome whereas the maximum score is 24 indicating a poor outcome.",[],"FEMALE","18 Years","44 Years",{"inclusion":63,"exclusion":64,"raw_text":65},[],[],"Inclusion Criteria:\n\n1. Patients willing and able to provide simple consent for registry participation.\n2. Has access to email, text messages via smartphone or computer with internet access\n3. Be between the ages of 18 to 44 years at enrollment.\n4. Pregnant with one fetus\u002Fbaby at time of enrollment (singleton pregnancy)\n5. Have headaches or migraines prior to pregnancy and continued to have headaches or migraines into pregnancy OR headaches or migraines began while pregnant in the first trimester.\n6. Able to provide proof of active intrauterine pregnancy and estimated due date, via online document upload, using any of the following documents:\n\n   1. ultrasound report of current pregnancy\n   2. beta hcg lab report\n   3. a signed provider's medical documentation confirming intrauterine pregnancy with fetal heart sounds and estimated due date\n   4. a signed provider's note on a prescription sheet or physician letterhead confirming intrauterine pregnancy and estimated due date\n\nExclusion Criteria:\n\n1. Patients under the age of 18 or over the age of 44 at enrollment\n2. Not pregnant at time of enrollment\n3. Pregnant with more than one fetus\u002Fbaby at time of enrollment (multigestational pregnancy)\n4. Patients with any other condition which might preclude participation in the opinion of the patient's physician(s) or the study's principal investigator\n5. No access to email, smartphone, or computer with internet access",[67],"ADULT",[69],{"facility":70,"status":8,"city":71,"state":72,"zip":73,"country":74,"contacts":75,"geoPoint":83},"https:\u002F\u002Fpublic.smart-trial.co\u002F#\u002Fpublic\u002F649d77f0e8f8d0fb993d0c61\u002F6626f6a04f0a3c7dd0860e14\u002F662726d84f0a3c7dd08aeaa0\u002Fsignup?lang=en-us&enforceLanguage=true","Darien","Connecticut","06820","United States",[76,81],{"name":77,"role":78,"phone":79,"email":80},"Lilliana Delmonico","CONTACT","(475) 270-1033","l.delmonico@cefaly.com",{"name":82,"role":78},"Michael Johnson",{"lat":84,"lon":85},41.07871,-73.46929,[87,91],{"name":88,"role":78,"phone":89,"email":90},"Michael A.L. Johnson, MD","203-309-3776","Clinicaltrial@cefaly.com",{"name":92,"role":78,"phone":89,"email":90},"Gregory Panza, PhD",[94],{"name":95,"role":96},"Deena Kuruvilla, MD","PRINCIPAL_INVESTIGATOR",[98,102,105,108,111,114,117,120,123,126,129,132],{"pmid":99,"type":100,"citation":101},"35456034","BACKGROUND","Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390\u002Fcells11081355.",{"pmid":103,"type":100,"citation":104},"31069791","Skajaa N, Szepligeti SK, Xue F, Sorensen HT, Ehrenstein V, Eisele O, Adelborg K. Pregnancy, Birth, Neonatal, and Postnatal Neurological Outcomes After Pregnancy With Migraine. Headache. 2019 Jun;59(6):869-879. doi: 10.1111\u002Fhead.13536. Epub 2019 May 8.",{"pmid":106,"type":100,"citation":107},"23992560","Frederick IO, Qiu C, Enquobahrie DA, Aurora SK, Peterlin BL, Gelaye B, Williams MA. Lifetime prevalence and correlates of migraine among women in a pacific northwest pregnancy cohort study. Headache. 2014 Apr;54(4):675-85. doi: 10.1111\u002Fhead.12206. Epub 2013 Aug 28.",{"pmid":109,"type":100,"citation":110},"34517247","Welander NZ, Mwinyi J, Asif S, Schioth HB, Skalkidou A, Fransson E. Migraine as a risk factor for mixed symptoms of peripartum depression and anxiety in late pregnancy: A prospective cohort study. J Affect Disord. 2021 Dec 1;295:733-739. doi: 10.1016\u002Fj.jad.2021.08.119. Epub 2021 Sep 4.",{"pmid":112,"type":100,"citation":113},"28685258","Friedman LE, Aponte C, Perez Hernandez R, Velez JC, Gelaye B, Sanchez SE, Williams MA, Peterlin BL. Migraine and the risk of post-traumatic stress disorder among a cohort of pregnant women. J Headache Pain. 2017 Dec;18(1):67. doi: 10.1186\u002Fs10194-017-0775-5. Epub 2017 Jul 6.",{"pmid":115,"type":100,"citation":116},"35332216","Kuruvilla DE, Mann JI, Tepper SJ, Starling AJ, Panza G, Johnson MAL. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Sci Rep. 2022 Mar 24;12(1):5110. doi: 10.1038\u002Fs41598-022-09071-6.",{"pmid":118,"type":100,"citation":119},"16717171","Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001\u002Farchinte.166.10.1092.",{"pmid":121,"type":100,"citation":122},"3651732","Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987 Jun;150:782-6. doi: 10.1192\u002Fbjp.150.6.782.",{"pmid":124,"type":100,"citation":125},"26719105","Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31. doi: 10.1016\u002Fj.genhosppsych.2015.11.005. Epub 2015 Nov 18.",{"pmid":127,"type":100,"citation":128},"33269942","Wood ME, Burch RC, Hernandez-Diaz S. Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine. Cephalalgia. 2021 Mar;41(3):392-403. doi: 10.1177\u002F0333102420975394. Epub 2020 Dec 3.",{"pmid":130,"type":100,"citation":131},"31579938","Burch R. Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review. Headache. 2020 Jan;60(1):200-216. doi: 10.1111\u002Fhead.13665. Epub 2019 Oct 3.",{"pmid":133,"type":100,"citation":134},"33069326","GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016\u002FS0140-6736(20)30925-9.",[136],{"label":137,"url":138},"Headaches.com","https:\u002F\u002Fwww.headaches.com\u002F",{"nct_id":4,"conditions":140,"biomarkers":141},[20,19],[],{"nct_id":4,"found":143,"summary":144,"prompt_version":154},true,{"design":145,"status":146,"heading":147,"summary":148,"follow_up":149,"word_count":150,"commitments":151,"compensation":152,"drugs_mentioned":153},"This is an observational study, meaning researchers will collect information without making changes to your treatment. It aims to enroll 550 pregnant women.","completed","External Trigeminal Nerve Stimulation for Migraine During Pregnancy","This online registry is studying how safe and effective external trigeminal nerve stimulation (e-TNS), marketed as CEFALY, is for treating migraines in pregnant women. CEFALY is a non-invasive, non-drug device approved by the FDA for migraine treatment. You can join if you are a woman between 18 and 44 years old, pregnant with one baby, and have access to email or text. You don't need to use CEFALY or any other migraine treatment to participate. The study will look at miscarriage rates and how mothers bond with their babies after birth. The goal is to see if CEFALY is a good option for migraines during and after pregnancy. The study is currently unclear on its recruitment status and aims to enroll 550 participants.","Your progress will be tracked through study completion, which is an average of 2 years.",123,"You will complete online surveys for screening, enrollment, and data collection. There are no clinic or research visits.","Not stated in the trial record.",[45],"v2"]